The efficacy of Nefopam for prevention of catheter-related bladder discomfort in patients undergoing transurethral resection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008932

Enrollment

138

Registered

2023-11-09

Start date

2018-11-23

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The patient group is randomly divided into three groups: C (control) group, which is the control group, and N20 (nefopam 20 mg) group and N40 (nefopam 40 mg) group, which are experimental group

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: It is intended for male patients between the ages of 20 and 69 who are scheduled for transurethral resection of bladder or transurethral resection of prostate.

Exclusion criteria

Exclusion criteria: Patients with a history of epilepsy or convulsions, myocardial infarction, patients receiving MAO inhibitors or a history of hypersensitivity to these drugs, and patients with angle-closure glaucoma are excluded.

Design outcomes

Primary

Measure	Time frame
indicendy of CRBD	—

Secondary

Measure	Time frame
CRBD severity	—

Countries

Korea, Republic of

Contacts

Public ContactHearim Chun

Soon Chun Hyang University Hospital Cheonan

blau00@schmc.ac.kr+82-41-570-2829

Outcome results